Previous studies have demonstrated that the maximum benefit of histologic grade assessment would be in the subgroup of patients with early ER‐positive/HER2‐negative (ER+HER2−) tumors [3, 4, 5, 6, 7, 8], which contributes to 60–70% of all breast cancer [9]. This evidence concerns the gene ESR1 and breast carcinoma.